Actively Recruiting
Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy
Led by Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Updated on 2026-04-14
93
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of the trial is the early detection of cardiotoxicity in patients treated with anthracycline-based chemotherapy. Current diagnostics, such as troponin T, NT-pro-BNP, electrocardiogram, and echocardiography, are not able to identify early myocardial damage. Therefore, this study aims to identify early myocardial damage by using cardiac magnetic resonance imaging. The primary endpoint of this study is the change in relaxation times in CMR before, during, and after therapy. Furthermore, the study analyzes: * other abnormal results in CMR * changes in troponin T and NT-pro-BNP * changes in global longitudinal strain in echocardiography and correlation with results of CMR * detection of new biomarkers in blood, urine, or stool
CONDITIONS
Official Title
Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients recommended for cancer treatment including at least four doses of anthracycline chemotherapy
You will not qualify if you...
- Unable to provide informed consent
- Prior treatment with anthracyclines
- Use of cardiotoxic drugs like high-dose cyclophosphamide, HER2 inhibitors, VEGF inhibitors, BCR-ABL inhibitors, BRAF inhibitors, MEK inhibitors, or immune checkpoint inhibitors within the last 6 months
- Planned invasive heart procedures during the study
- Heart involvement from other diseases such as amyloidosis
- Receiving fewer than four anthracycline doses
- Use of liposomal anthracycline formulations
- Anthracyclines not given in every chemotherapy cycle
- Prior chest radiation involving the heart before anthracycline treatment
- Participation in another clinical trial currently or within the last 3 months
- Kidney function below specified threshold (GFR < 30 ml/min/1.73 m²)
- Around the time of liver transplantation surgery
- Contraindications to cardiac MRI, including metallic implants like pacemakers
- Pregnancy or breastfeeding
- Allergy or intolerance to gadolinium-based contrast agents
- Vulnerable populations such as individuals unable to consent or prisoners
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Robert Bosch Gesellschaft für Medizinische Forschung mbH
Stuttgart, Germany, 70376
Actively Recruiting
Research Team
M
Matthias Prof. Dr. med. Schwab
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here